LAVA Therapeutics NV
NASDAQ:LVTX
LAVA Therapeutics NV
Research & Development
LAVA Therapeutics NV
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Research & Development
-$28.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Research & Development
-$98.2m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-21%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Research & Development
-€45.4m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-8%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Research & Development
-$134.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-9%
|
|
|
argenx SE
XBRU:ARGX
|
Research & Development
-$1.4B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-51%
|
|
|
Merus NV
NASDAQ:MRUS
|
Research & Development
-$328.5m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-35%
|
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
See Also
What is LAVA Therapeutics NV's Research & Development?
Research & Development
-28.5m
USD
Based on the financial report for Dec 31, 2024, LAVA Therapeutics NV's Research & Development amounts to -28.5m USD.
What is LAVA Therapeutics NV's Research & Development growth rate?
Research & Development CAGR 5Y
-28%
Over the last year, the Research & Development growth was 13%. The average annual Research & Development growth rates for LAVA Therapeutics NV have been 9% over the past three years , -28% over the past five years .
